BioSpace News Archive

FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company’s corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https:/

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, announced it will release financial results for the first quarter ended March 31, 2020, after market close on Wednesday, May 6, 2020.

As VisiQuate Inc. continues to grow and expand into new areas of healthcare, the company today announced that Jim Lacy and Karl Robb, both of whom are widely known and highly respected figures in their industries, have joined its Board of Directors.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement for the 2020 annual general meeting of shareholders. The annual general meeting of Aptose shareholders will be held on June 2, 2020 at 10:00 a.m. Pacific time in an online only format. There w

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A. focused on research and development of treatments for rare and ultra-rare disorders, today announced its support for Fabry Disease Awareness Month and highlighted the company’s continued commitment to patients, caregivers and families impacted by this debilitating rare disease

Incyte (Nasdaq:INCY) announces the appointment of Christine Lennon as the General Manager for Incyte Biosciences Canada, expanding the Company’s North American footprint. In her role, Christine will be responsible for the development of Incyte’s medical, regulatory and commercial strategy in Canada. “We are very pleased that Christine has joined Incyte as we expand our business in North America and establish a commercial

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in May. Details of the conferences and management presentation are as foll

Verde® Environmental Technologies, Inc., maker of Deterra® Drug Deactivation and Disposal System today announced a partnership with national nonprofit SAFE Project to prevent drug abuse by increasing access to safe medication disposal resources

- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes - - Abstracts Published Online Today in Obstetrics & Gynecology (The Green Journal) - [24-April-2020] SAN DIEGO , April 24, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a cli

Dr. Akrum “Aki” Alzubaidi, an Interventional Pulmonologist at National Jewish Health, and founder and co-CEO of Eon, will be joined by the Essential Patient Taskforce for a live webinar on April 29.